Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RevvityRVTY +0.37%78 12-1 Month Momentum % is 29.60% as of Aug. 08, 2026. GuruFocus rates RVTY with a GF Score™ of 78/100 and a GF Value™ of $117.91 (Fairly Valued). The stock has 11 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Revvity ranks better than 77.36% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-08), Revvity's 12-1 Month Momentum % is 29.60%.
The industry rank for Revvity's 12-1 Month Momentum % or its related term are showing as below:
RVTY's 12-1 Month Momentum % is ranked better than 77.36% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -5.895
vs RVTY: 29.60
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Revvity 12-1 Month Momentum % Related Terms
RVTY vs ICLR, CRL, QGEN: 12-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Revvity's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revvity 12-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Revvity's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revvity (RVTY) has a 12-1 Month Momentum % of 29.60% as of Aug. 08, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Revvity and its competitors. According to the industry distribution chart, Revvity ranks #48 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 22.6%.
Is Revvity's 12-1 Month Momentum % too high?
Revvity's current 12-1 Month Momentum % is 29.60%. Based on the distribution chart, Revvity ranks #48 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Revvity has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Revvity's 12-1 Month Momentum % compare to ICLR and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Revvity ranks #48 out of 212 companies for 12-1 Month Momentum %. This places Revvity in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 12-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Revvity and its competitors. Revvity's current 12-1 Month Momentum % is 29.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revvity stock overvalued right now?
Based on GuruFocus' analysis, Revvity (RVTY) is currently considered Fairly Valued. The stock's GF Value™ is $117.91, compared to a current price of $114.66 — trading 2.8% below its estimated fair value. The current 12-1 Month Momentum % is 29.60%. Revvity's overall GF Score™ is 78/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Revvity (RVTY), the current 12-1 Month Momentum % is 29.60% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revvity (RVTY) Overvalued in 2026?
Based on GuruFocus' analysis, Revvity stock appears to be undervalued.
The current stock price of $114.66 is trading 2.8% below its estimated GF Value™ of $117.91.
GuruFocus considers Revvity to be Fairly Valued.
Key valuation signals for RVTY:
12-1 Month Momentum %: 29.60%
GF Value™: $117.91 vs. price of $114.66 (2.8% below fair value)
No single metric tells the full story. See the RVTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
78GF Score
Get the complete analysis for RVTY
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVTY has been successfully added to your 
